CLAIMS

1. Compound of formula (A):



(A)

in which:

- all of the above entity, with the exception of the substituent X, is called M6G-N(R_2)R_1-S-

- R_1 represents a linear or branched C_1-C_{10} alkyl group, unsubstituted or substituted by at least one substituent, the alkyl chain being optionally interrupted by one or more heteroatoms chosen from O, S and N;

- R_2 represents hydrogen, a linear or branched C_1-C_5 alkyl group or an aryl, heteroaryl or (C_1-C_5) alkylaryl group, unsubstituted or substituted by a C_1-C_4 alkyl;

- X represents hydrogen, an M6G-N(R_2)R_1-S- residue or a polymer linked with the rest of the entity by a spacer arm;

- the asymmetric carbons present in the formula (A) can have the R or S configuration,

as well as its pharmaceutically acceptable salts.

2. Compound according to claim 1, characterized in that

- R_1 and R_2 are as defined in claim 1;

- X represents an M6G-N(R_2)R_1-S- residue, the two M6G-N(R_2)R_1-S- residues constituting the compounds of formula (A) in dimer form being identical or different.

3. Compound according to claim 1, characterized in that

- R_1 is as defined in claim 1;

- R_2 represents hydrogen, and

- X represents hydrogen.

4. Compound according to claim 1 or 2, characterized in that

- R_1 is as defined in claim 1;

- R_2 represents hydrogen, and

- X represents an M6G-N(R_2)R_1-S- residue in which R_1 and R_2 are as defined above.

5. Compound according to any one of claims 1 to 4, characterized in that R_1 represents an alkyl group substituted by one or more substituents chosen from: a C_1-C_5 alkyl group; an amino group; a $COOR_3$ group; a $CONR_3R_4$ group, R_3 and R_4 in the $COOR_3$ or $CONR_3R_4$ groups independently representing hydrogen, an optionally substituted C_1-C_{20} alkyl, an aryl, a heteroaryl or an alkylaryl group; a C_1-C_{20} ketone and a C_1-C_{20} aldehyde.

6. Compound according to claims 1 or 3, characterized in that R_1 represents -$(CH_2)_2$-, R_2 is hydrogen and X is hydrogen.

7. Compound according to any one of claims 1, 2 or 4, characterized in that R_1 represents -$(CH_2)_2$-, R_2 is hydrogen and X is an M6G-N(R_2)R_1-S- residue in which R_1 = -$(CH_2)_2$- and R_2 is hydrogen.

8. Compound according to any one of claims 1, 2 or 4, characterized in that

- R_1 represents a -CH($COOR_3$)-CH_2- group in which R_3 represents hydrogen, methyl, ethyl, propyl or butyl,

- R_2 represents hydrogen,

- X represents hydrogen or an M6G-N(R_2)R_1-S- residue in which R_1 = -CH($COOR_3$)-CH_2- in which R_3 is as defined above and R_2 is hydrogen.

9. Compound according to one of claims 1 or 5, characterized in that

- R_1 represents a -CH($CONR_3R_4$)-CH_2- group in which R_3 and R_4 represent hydrogen, methyl, ethyl, propyl or butyl,

- R_2 represents hydrogen,

- X represents hydrogen or an M6G-N(R_2)R_1-S- residue in which R_1 = -CH($CONR_3R_4$)-CH_2- in which R_3 and R_4 are as defined above and R_2 is hydrogen.

10. Compound according to claims 1 or 5, characterized in that

- R_1 represents a $-CH(COOR_3)-C(CH_3)_2-$ group in which R_3 represents hydrogen, methyl, ethyl, propyl or butyl,

- R_2 represents hydrogen

- X represents hydrogen or an M6G-$N(R_2)R_1$-S- residue in which R_1 = $-CH(COOR_3)-C(CH_3)_2-$ in which R_3 is as defined above and R_2 is hydrogen.

11. Compound according to claims 1 or 5, characterized in that

- R_1 represents a $-CH(COOR_3)-(CH_2)_2-C(O)NHCH(R_5)-CH_2-$ group, in which R_3 represents hydrogen, methyl, ethyl, propyl or butyl and R_5 represents $-C(O)-NH-CH_2-COOR_3$,

- R_2 represents hydrogen

- X represents hydrogen or an M6G-$N(R_2)R_1$-S- residue in which R_1 = $-CH(COOR_3)-(CH_2)_2-C(O)NHCH(R_5)-CH_2-$ in which R_3 and R_5 are as defined above and R_2 represents hydrogen.

12. Compound according to claim 1, characterized in that

- R_1 represents a $-(CH_2)_2-$ group,

- R_2 represents hydrogen

- X represents a polymer linked to the rest of the entity by a spacer arm of formula $-S-(CH_2)_n-NH-C(O)-$ in which n = 0 to 4 and said polymer is a polyethylene glycol of molecular weight (Mw) greater than or equal to 10000.

13. Method for the preparation of a compound of formula (A) according to any one of claims 1 to 12, characterized in that it comprises the stages consisting of reacting morphine-6-glucuronide with a compound of formula (III) $NHR_2-R_1-S-S-R_1-NHR_2$, in which R_1 and R_2 are as defined in any one of claims 1 to 11, in the presence of a coupling agent, and reducing the disulphide bridge using a reducing agent if necessary.

14. Method for the preparation of a compound of formula (A) according to any one of claims 1 to 11, in which X = H, characterized in that it comprises the stages consisting of reacting morphine-6-glucuronide with a compound of formula (IV) NHR_2-R_1-SH, in which R_1 and R_2 are as defined in any one of claims 1 to 12, in the presence of a coupling agent and reducing *in situ* the oxidation by-products using a reducing agent.

15. Method according to one of claims 13 or 14, characterized in that the coupling agent is chosen from benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP), dicyclohexylcarbodiimide (DCC), DCC combined with hydroxybenzotriazole (DCC/HOBT) and diisopropylcarbodiimide combined with HOBT (DIPCDI/HOBT).

16. Method according to one of claims 13 or 14, characterized in that the reducing agent is chosen from tris(2-carboxyethyl)phosphine, triphenylphosphine, tris(hydroxymethyl)-phosphine and dithiothreitol.

17. Pharmaceutical composition, characterized in that it contains a compound of formula (A) according to any one of claims 1 to 12 and a pharmaceutically acceptable vehicle.

18. Pharmaceutical composition according to claim 17, characterized in that it is in a form which can be administered by parenteral route.

19. Pharmaceutical composition according to claim 17, characterized in that it is in the form of a preparation which can be injected by sub-cutaneous, intravenous or intramuscular route.

20. Pharmaceutical composition according to claim 19, characterized in that it is in a form which can be administered by oral route.

21. Pharmaceutical composition according to claim 20, characterized in that it has a sustained or controlled activity.

22. Use of a compound according to any one of claims 1 to 12 or a pharmaceutical composition according to any one of claims 17 to 21, for the production of a medicament intended for the treatment of pain.